<DOC>
	<DOCNO>NCT01554800</DOCNO>
	<brief_summary>This study phase 1 , intravenous , open-label , single-dose escalation study evaluate safety , tolerability , pharmacokinetics pharmacodynamics ACP-501 ( recombinant human Lecithin Cholesterol Acyl Transferase ( rhLCAT ) ) subject coronary artery disease ( CAD ) . Four cohort consist 4 subject receive one dose ACP-501 . The dose escalate cohort .</brief_summary>
	<brief_title>Effect ACP-501 Safety , Tolerability , Pharmacokinetics Pharmacodynamics Subjects With Coronary Artery Disease</brief_title>
	<detailed_description>After sign informed consent , subject enter trial follow 8 week include : 4 week screen , entry criterion assessment Day 0 single-dose IV infusion Day 1 , 4 week follow-up .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>A history stable document CAD Currently nonsmoking male female age 30 85 year inclusive . Female subject childbearing potential ( neither pregnant breastfeeding ) must use adequate birth control study conduct . Chronic concomitant medication must stable least 2 month prior screen HDLC &lt; 50 mg/dL men &lt; 55 mg/dL woman Body Mass Index ( BMI ) approximately 18 35 kg/m^2 ; total body weight &gt; = 50 kg ( 110 lb ) &lt; = 110 kg ( approximately 242 lb ) Myocardial infarction , stroke , coronary intervention/revascularization procedure within 6 month prior dose . Chronic heart failure ( &gt; New York Heart Association ( NYHA ) Functional Classification II ) . Ventricular tachyarrhythmias . Uncontrolled Type 2 ( HbA1c &gt; 8.5 % ) Type 1 diabetes mellitus . History febrile illness within 5 day prior dose . History regular alcohol consumption exceed 10 drink per week . 12lead ECG demonstrate QTc &gt; 500 msec screening . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate trial participation investigational product administration may interfere interpretation trial result , judgment investigator , would make subject inappropriate entry trial .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Lecithin Cholesterol Acyl Transferase</keyword>
	<keyword>LCAT</keyword>
	<keyword>rhLCAT</keyword>
	<keyword>Enzyme replacement therapy</keyword>
	<keyword>High-Density Lipoprotein ( HDL )</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>Cholesterol ester</keyword>
	<keyword>LCAT Deficiency</keyword>
</DOC>